Vadim Koshkin, MD

About $74 million in US govt funding (including NIH) went into developing enzalutamide - a multibillion dollar drug that prolonged life for countless men with prostate cancer. Why would anyone cut this support? We need more, not less! @ascocancer.bsky.social @theaacr.bsky.social

23.02.2025 19:11 — 👍 11    🔁 6    💬 1    📌 0

Comparison of Adjuvant regimens for cancer across tumor types #GU25. Nivolumab per Checkmate 274 for #bladdercancer rises to the top. docs.google.com/presentation...

15.02.2025 15:36 — 👍 7    🔁 3    💬 0    📌 0

Would love to be included Tian. Thanks for organizing!

04.02.2025 04:32 — 👍 1    🔁 0    💬 1    📌 0

Pembrolizumab Retreatment in Patients with Advanced or Metastatic Urothelial Carcinoma Who Responded to First-course Pembrolizumab-based Therapy Patients with metastatic solid tumors who previously had stable disease or a response with immunotherapy may derive benefit from immunotherapy retreat…

First post on this platform highlighting an important article.
Pembro rechallenge for mUC pts published in @euplatinum.bsky.social
Pts with response on Pembro stop Rx👉PD👉resume Pembro
Rechallenge works: ORR: 41% mOS: 26 mos
👇
Pembrolizumab Retreatment in mUC www.sciencedirect.com/science/arti...

04.02.2025 04:17 — 👍 4    🔁 0    💬 0    📌 0